Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Immix Biopharma, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 22 | 23 | +1 |
| Shares | 2.92M | 2.26M | −656.2K (−22.5%) |
| Value | $4.90M | $4.68M | −$219.9K (−4.5%) |
New holders (5)
Institutions that held Immix Biopharma, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Velan Capital Investment Management LP | 25,000 | $51.8K | 0.05% |
| Tritonpoint Wealth, LLC | 24,526 | $50.8K | 0.00% |
| Virtu Financial LLC | 17,846 | $37.0K | 0.00% |
| Royal Bank of Canada | 11,168 | $23.0K | 0.00% |
| Raymond James Financial Inc | 525 | $1.09K | 0.00% |
Sold out (4)
Institutions that held Immix Biopharma, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Cable Car Capital LLC | 779,358 | $1.31M |
| XTX Topco Ltd | 12,833 | $21.6K |
| FNY Investment Advisers, LLC | 11,250 | $18.0K |
| JPMorgan Chase & Co | 35 | $59 |